(Q28484913)

English

Combination of a proteomics approach and reengineering of meso scale network models for prediction of mode-of-action for tyrosine kinase inhibitors

scientific article

In more languages

Statements

scholarly article

0 references

Combination of a proteomics approach and reengineering of meso scale network models for prediction of mode-of-action for tyrosine kinase inhibitors (English)

0 references

Andreas Schuppert

object named as

Andreas Schuppert

12

0 references

Christian Scharf

object named as

Christian Scharf

5

0 references

Carsten Bokemeyer

9

object named as

Carsten Bokemeyer

0 references

author name string

Stefan Balabanov

1

0 references

Thomas Wilhelm

2

0 references

Simone Venz

3

0 references

Gunhild Keller

4

0 references

Heike Pospisil

6

0 references

Melanie Braig

7

0 references

Christine Barett

8

0 references

Reinhard Walther

10

0 references

Tim H Brümmendorf

11

0 references

language of work or name

0 references

publication date

2013

0 references

0 references

8

0 references

1

0 references

e53668

0 references

copyright license

Creative Commons Attribution 4.0 International

9 January 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Prediction of drug combinations by integrating molecular and pharmacological data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

19 March 2017

Identification of candidate small-molecule therapeutics to cancer by gene-signature perturbation in connectivity mapping

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

19 March 2017

Analysis of compound synergy in high-throughput cellular screens by population-based lifetime modeling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

19 March 2017

Identifying drug effects via pathway alterations using an integer linear programming optimization formulation on phosphoproteomic data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

19 March 2017

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

19 March 2017

Charting the molecular network of the drug target Bcr-Abl

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

19 March 2017

A quantitative analysis of kinase inhibitor selectivity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

19 March 2017

Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

19 March 2017

Chemogenomic profiling on a genome-wide scale using reverse-engineered gene networks

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

19 March 2017

Inferring genetic networks and identifying compound mode of action via expression profiling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

19 March 2017

Functional discovery via a compendium of expression profiles

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

19 March 2017

The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

7 April 2017

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

7 April 2017

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

7 April 2017

Protein kinases--the major drug targets of the twenty-first century?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

7 April 2017

A small molecule-kinase interaction map for clinical kinase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

7 April 2017

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

7 April 2017

The specificities of protein kinase inhibitors: an update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

9 May 2017

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

29 September 2017

Expression of eukaryotic initiation factor 5A and hypusine forming enzymes in glioblastoma patient samples: implications for new targeted therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

29 September 2017

Combinatorial drug therapy for cancer in the post-genomic era.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

29 September 2017

Peroxiredoxins 3 and 4 are overexpressed in prostate cancer tissue and affect the proliferation of prostate cancer cells in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

29 September 2017

Proteomic profiling of germ cell cancer cells treated with aaptamine, a marine alkaloid with antiproliferative activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

29 September 2017

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

29 September 2017

A novel method of transcriptional response analysis to facilitate drug repositioning for cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

29 September 2017

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

29 September 2017

Discovery and preclinical validation of drug indications using compendia of public gene expression data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

29 September 2017

Predicting drug side-effect profiles: a chemical fragment-based approach

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

29 September 2017

Identification of clinically relevant protein targets in prostate cancer with 2D-DIGE coupled mass spectrometry and systems biology network platform

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

29 September 2017

Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

29 September 2017

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

29 September 2017

Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

29 September 2017

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

29 September 2017

Transglutaminase 2: a multi-functional protein in multiple subcellular compartments

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

29 September 2017

Predictive mesoscale network model of cell fate decisions during C. elegans embryogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

29 September 2017

Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

29 September 2017

A modular approach for integrative analysis of large-scale gene-expression and drug-response data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

29 September 2017

Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

29 September 2017

Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

29 September 2017

Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

29 September 2017

Mechanisms of drug inhibition of signalling molecules

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

29 September 2017

Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

29 September 2017

Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

29 September 2017

Issues and progress with protein kinase inhibitors for cancer treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

29 September 2017

Chemical combination effects predict connectivity in biological systems

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541187

2 June 2018

Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0053668

21 January 2018

An algorithmic framework for predicting side effects of drugs.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0053668

21 January 2018

Systems biology and combination therapy in the quest for clinical efficacy.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0053668

21 January 2018

The mode-of-action by network identification (MNI) algorithm: a network biology approach for molecular target identification.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0053668

21 January 2018

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0053668

21 January 2018

Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0053668

21 January 2018

A computational algebra approach to the reverse engineering of gene regulatory networks

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0053668

21 January 2018

Mass spectrometry in high-throughput proteomics: ready for the big time.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0053668

21 January 2018

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0053668

21 January 2018

Proteomics analysis of cellular imatinib targets and their candidate downstream effectors

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0053668

21 January 2018

The Bcr-Abl kinase regulates the actin cytoskeleton via a GADS/Slp-76/Nck1 adaptor protein pathway

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0053668

21 January 2018

Efficient reengineering of meso-scale topologies for functional networks in biomedical applications

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0053668

21 January 2018

Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach

1 reference

https://pubmed.ncbi.nlm.nih.gov/23326482

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex

1 reference

https://pubmed.ncbi.nlm.nih.gov/23326482

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0053668

0 references

2013PLoSO...853668B

0 references

PMC publication ID

0 references

PubMed publication ID

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28484913&oldid=2114494542"